This article is a US Government work and, as such, is in the public domain in the United States of America.
Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention †
Version of Record online: 8 MAR 2002
Copyright © 2002 Wiley-Liss, Inc.
Environmental and Molecular Mutagenesis
Volume 39, Issue 2-3, pages 264–270, 2002
How to Cite
Zujewski, J. (2002), Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention . Environ. Mol. Mutagen., 39: 264–270. doi: 10.1002/em.10054
- Issue online: 29 MAR 2002
- Version of Record online: 8 MAR 2002
- Manuscript Accepted: 1 DEC 2001
- Manuscript Revised: 5 NOV 2001
- Manuscript Received: 25 SEP 2001
- selective estrogen receptor modulator;
- insulin-like growth factor 1
Tamoxifen has been shown to decrease the risk of invasive breast cancer by 49% and noninvasive breast cancer by 50%. Tamoxifen is also associated with a threefold increased risk of endometrial cancer. Raloxifene, a second-generation selective estrogen receptor modulator (SERM), has not been associated with endometrial cancer risk, and is currently under study in a large, multi-institutional, randomized Study of Tamoxifen and Raloxifene (STAR) for breast cancer prevention in postmenopausal women. A pilot trial of raloxifene in premenopausal women to assess the safety, tolerability, effects on bone mineral density, mammographic density, and other biological endpoints is ongoing. The retinoids have been shown to decrease mammary tumors in rodent carcinogenesis models. The Italian trial of fenretinide (4-HPR) in women with stage I breast cancer randomized women to fenretinide or no intervention. This study did not show an overall effect of decreasing the risk of contralateral breast cancer. However, a protective effect was suggested in premenopausal women. It has been suggested that this effect may be related to insulin-like growth factor 1 (IGF-1), which has been shown to be modulated by fenretinide in premenopausal but not postmenopausal women. Pilot studies of SERMs alone and in combination with retinoids or other agents provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women. These studies can provide information as to both the pathophysiology of carcinogenesis and the mechanism of action of chemopreventive agents, and help select agents and doses for testing in large randomized studies. Environ. Mol. Mutagen. 39:264–270, 2002. Published 2002 Wiley-Liss, Inc.